Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3079514 · 1 trial · 1 indication
An SAE is an adverse event that results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. A summary of SAEs, regardless of causality, is located in the Reported Adverse Events module.
| Arm | Type | Description |
|---|---|---|
| LY3079514 | EXPERIMENTAL | Single dose of LY3079514 administered intravenous (IV) or subcutaneous (SC) during a single occasion |
| Placebo | PLACEBO_COMPARATOR | Single dose of placebo matching LY3079514 administered IV infusion or SC injection during a single occasion. |
| Name | Type | Description |
|---|---|---|
| LY3079514 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Overtly healthy participants as determined by medical history and physical examination * To qualify as Japanese for the purpose of this study, the Japanese participant must be first-generation Japanese * Have a body mass index (BMI) between 18.5 and 32.0 kilograms per square m...
LY3079514 is an investigational small molecule developed by Eli Lilly and Company. It has been studied in a Phase 1 clinical trial in healthy adult volunteers in the United States. The specific disease or condition it is intended to treat has not been publicly disclosed, and it remains in early clinical development.
LY3079514 is made and developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored the Phase 1 study of the compound conducted in healthy participants in the United States.
LY3079514 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The study enrolled 48 healthy participants and was randomized, double-blind, and placebo-controlled. The compound has not been approved by the FDA and remains investigational.
LY3079514 has been evaluated in one completed Phase 1 trial, NCT02242903, titled A Study of LY3079514 in Healthy Participants. The trial enrolled 48 healthy volunteers aged 18 years and older in the United States. It used a randomized, double-blind, placebo-controlled design. No active trials of LY3079514 are currently listed.
LY3079514 has been studied only in healthy volunteers in a Phase 1 trial, so no therapeutic use has been established. The target indication for LY3079514 has not been publicly disclosed. It is an investigational small molecule and is not approved for any condition.